BlueWind Medical
Medinat HaYehudim Street 85
Herzliya
4676670
About BlueWind Medical
BlueWind Medical was founded in 2010 by the premier Israeli innovation and investment company Rainbow Medical. The company is developing a platform technology of miniature wireless neurostimulators that can be placed in a minimally invasive procedure and treat multiple indications. BlueWind Medical is led by a team of experienced and dedicated engineers and researchers that strive for the highest quality products and most advanced engineering processes. By putting the patients' needs first, Bluewind is able to create a versatile and effective platform that will transform Neurostimulation as we know it.YEAR FOUNDED:
2010
LEADERSHIP:
CEO: Guri Oron Bluewind
19 articles about BlueWind Medical
-
Patients in Utah Now Have Access to the Novel Revi™ Implantable Tibial Neuromodulation Device for the Treatment of Urge Urinary Incontinence
3/27/2024
BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient-centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Utah with urologist Dr. Sara Lenherr at the University of Utah.
-
First Patient in the RESTORE Clinical Study of Revi™ System for Urge Urinary Incontinence Treated in Tampa, Florida
2/28/2024
BlueWind Medical, Ltd. today announced that Dr. Osvaldo Padron of Florida Urology Partners in Tampa, Florida, has treated the first patient in the RESTORE study, a prospective, multi-center, open label, post market, randomized controlled trial.
-
BlueWind Medical Brings Revi™ Implantable Tibial Neuromodulation Device to Patients in Central Ohio
2/7/2024
BlueWind Medical, Ltd., a pioneer in the development and commercialization of a patient centric implantable Tibial NeuroModulation (iTNM) solution for urge urinary incontinence (UUI), is excited to announce that Revi is now available in Springfield, Ohio at Ohio Valley Surgical Hospital with urologist Dr. Eric Espinosa.
-
BlueWind Medical's Revi™ System Secures U.S. FDA De Novo Classification Grant for the Treatment of Urgency Incontinence
8/17/2023
BlueWind Medical, Ltd. today announced that the US Food and Drug Administration (FDA) granted a De Novo marketing request for the Revi System, a transformative tibial neuromodulation therapy for the treatment of the symptoms of urgency incontinence alone or in combination with urinary urgency.
-
Clinical Study Results of the BlueWind System for Patients with Overactive Bladder Featured at the 2023 AUA Annual Meeting
5/1/2023
BlueWind Medical, Ltd., the developer of a transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced results from the OASIS pivotal trial evaluating the safety and efficacy of the BlueWind System in the treatment of OAB.
-
BlueWind Medical to Present Positive Results from its Pivotal Trial in Patients with Overactive Bladder at the 2023 AUA Annual Meeting
4/24/2023
BlueWind Medical, Ltd., the developer of transformative implantable tibial neuromodulation therapy for Overactive Bladder (OAB), today announced that efficacy results of the OASIS pivotal clinical study will be presented in a late breaking session at the American Urological Association (AUA) 2023 Annual Meeting, being held in Chicago April 27th- May 1st.
-
BlueWind Medical Announces Key Milestone as AMA Issues Unique Category III CPT Code for Subfascial Placement of Tibial Neurostimulators
3/8/2023
BlueWind Medical, Ltd. is pleased to announce that the American Medical Association has issued a new Current Procedural Terminology code for the subfascial implantation of a tibial neuromodulation device for Overactive Bladder.
-
BlueWind Medical Announces New Executive Appointments
11/1/2022
BlueWind Medical, Ltd., a medical device company transforming neuromodulation therapy for overactive bladder, announced three executive appointments to leadership positions within the company.
-
BlueWind Medical Appoints Dr. Liz Kwo to Board of Directors
9/27/2022
BlueWind Medical, Ltd. announced that Liz Kwo, M.D., MBA, MPH, Chief Medical Officer at Everly Health, has joined the company's Board of Directors.
-
BlueWind Medical Raises $64 Million to Fund Innovative Technology for Overactive Bladder (OAB) Treatment
5/9/2022
BlueWind Medical, Ltd., developer of the innovative RENOVA iStim implantable tibial neuromodulation device under investigation for the treatment of urgency incontinence alone or in combination with urinary urgency and/or urinary frequency, announced the closing of a $64 million Series B funding round.
-
BlueWind Medical Ltd. Appoints Charles F. Cargile as Chief Financial Officer
4/12/2022
BlueWind Medical, Ltd., developer of the innovative RENOVA iStim™ implantable tibial neuromodulation device for treatment of Overactive Bladder, announced the addition of Charles F. Cargile to its leadership team as Chief Financial Officer.
-
Bluewind Medical™ Ltd. Completes OASIS Study Patient Enrollment
11/16/2021
Bluewind Medical™, Ltd., today announced the successful completion of patient enrollment in the OASIS pivotal clinical study that will be the basis by which the company will seek US-FDA (Food & Drug Administration) marketing clearance in the United States.
-
BlueWind Medical Reaches 100th Patient for the OASIS Study of the RENOVA™ iStim System
7/6/2021
BlueWind Medical announces its 100th patient implant in their pivotal study for treating overactive bladder symptoms using an innovative medical device the RENOVA™ iStim.
-
BlueWind Medical Appoints Dan Lemaitre as Chief Executive Officer
1/6/2020
Mr. Lemaitre has served as Chairman of the Board of BlueWind Medical since November 2018.
-
BlueWind Medical Appoints New Executive Chairman
11/19/2018
Daniel Lemaitre brings more than three decades of medical device experience
-
BlueWind Medical Appoints Dr. Roger R. Dmochowski, MD, MMHC, as Chief Medical Officer
7/30/2018
BlueWind Medical announced today the appointment of Dr. Roger R. Dmochowski of Vanderbilt University as the company's chief medical officer (CMO).
-
BlueWind Medical Receives FDA Approval for Pivotal Trial Design of RENOVA iStim™ Implantable Tibial Nerve Neuromodulator for Overactive Bladder
6/14/2018
FDA has approved the company's pivotal study design for its RENOVA iStim (TM) system to support its marketing application in the US.
-
BlueWind Medical Announces the Publication of Breakthrough Results for BLUEWIND-RENOVA Implantabl...
1/4/2018
The scientific publication was published in the September issue of the Neuromodulation and Urodynamics journal. -
BlueWind Medical Announces CE-Mark For The BlueWind VIVENDI Miniature Implanted Wireless Stimulator To Treat Peripheral Pain
9/7/2016